UK markets closed

UCB SA (UCBJF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
106.000.00 (0.00%)
At close: 3:28PM EDT

UCB SA

AllEe de la Recherche, 60
Brussels 1070
Belgium
32 2 559 99 99
http://www.ucb.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees7,600

Key executives

NameTitlePayExercisedYear born
Mr. Jean-Christophe TellierCEO & Exec. DirectorN/AN/A1959
Ms. Kirsten Lund-JurgensenExec. VP of Supply & Technology SolutionsN/AN/A1959
Dr. Dhavalkumar D. Patel Ph.D., M.D.Exec. VP & Chief Scientific OfficerN/AN/A1961
Mr. William J. SilbeyExec. VP & Gen. CounselN/AN/A1959
Mr. Jean-Luc FleurialExec. VP & Chief HR OfficerN/AN/A1965
Prof. Iris Löw-FriedrichChief Medical Officer, Head of Devel. & Medical Patient Value Practices and Exec. VPN/AN/A1960
Mr. Emmanuel CaeymaexExec. VP of Immunology Solutions & Head of USN/AN/A1969
Mr. Charl Van ZylExec. VP of Neurology Solutions & Head of EU/InternationalN/AN/A1967
Ms. Sandrine DufourExec. VP & CFON/AN/A1967
Ms. Caroline VancoillieChief Accounting Officer & CFO of Patient Value FunctionsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.

Corporate governance

UCB SA’s ISS governance QualityScore as of 1 July 2021 is 3. The pillar scores are Audit: 3; Board: 5; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.